Trifluridine - Latest Advances

Gastric Carcinoma: Diagnosis, Staging, and Treatment.

Journal: Deutsches Arzteblatt international

Published: October 14, 2025

Granulocyte Colony Stimulating Factor in the Prevention of Chemotherapy-Induced Neutropenia in Patients With Colorectal Cancer Receiving Trifluridine/Tipiracil: A Real-World UK Retrospective Review.

Journal: Cancer control : journal of the Moffitt Cancer Center

Published: October 06, 2025

BOGO: A Proteome-Wide Gene Overexpression Platform for Discovering Rational Cancer Combination Therapies.

Journal: bioRxiv : the preprint server for biology

Published: September 15, 2025

Phase II Trial of TAS-102 in Colorectal Cancer Patients With Circulating Tumor DNA-Defined Minimal Residual Disease After Adjuvant Therapy: INTERCEPT-TT.

Journal: JCO precision oncology

Published: July 16, 2025

Study on drug sensitivity and clinical application of tumor organoid-based colorectal cancer models.

Journal: American journal of translational research

Published: July 09, 2025

CF10 Displayed Improved Activity Relative to 5-FU in a Mouse CRLM Model Under Conditions of Physiological Folate.

Journal: Cancers

Published: June 21, 2025

Efficacy and safety of TAS-102 plus Surufatinib in third and later line metastatic pancreatic cancer: a prospective, single center and biomarker exploratory, phase II study.

Journal: Molecular cancer

Published: May 29, 2025

Incorporation and Repair of Epigenetic Intermediates as Potential Chemotherapy Agents.

Journal: Molecules (Basel, Switzerland)

Published: May 28, 2025

Targeted therapy combined with immunotherapy vs trifluridine/tipiracil with bevacizumab as late-line therapy in metastatic colorectal cancer.

Journal: World journal of gastroenterology

Published: May 26, 2025

Tecovirimat is active against various MPXV strains, while cidofovir, brincidofovir, trifluridine, and gemcitabine have no detectable MPXV-specific antiviral activity.

Journal: Virus research

Published: May 23, 2025

Effect of a Biweekly Dosing Schedule on Severe Neutropenia Induced by Trifluridine/Tipiracil in Colorectal Cancer.

Journal: Anticancer research

Published: April 02, 2025

Comparison of standard and biweekly trifluridine/tipiracil plus bevacizumab regimens in advanced or recurrent colorectal cancer: a retrospective study.

Journal: Japanese journal of clinical oncology

Published: April 02, 2025

Filters

Gastric Carcinoma: Diagnosis, Staging, and Treatment.

Gastric Carcinoma: Diagnosis, Staging, and Treatment.

Granulocyte Colony Stimulating Factor in the Prevention of Chemotherapy-Induced Neutropenia in Patients With Colorectal Cancer Receiving Trifluridine/Tipiracil: A Real-World UK Retrospective Review.

Granulocyte Colony Stimulating Factor in the Prevention of Chemotherapy-Induced Neutropenia in Patients With Colorectal Cancer Receiving Trifluridine/Tipiracil: A Real-World UK Retrospective Review.

BOGO: A Proteome-Wide Gene Overexpression Platform for Discovering Rational Cancer Combination Therapies.

BOGO: A Proteome-Wide Gene Overexpression Platform for Discovering Rational Cancer Combination Therapies.

Phase II Trial of TAS-102 in Colorectal Cancer Patients With Circulating Tumor DNA-Defined Minimal Residual Disease After Adjuvant Therapy: INTERCEPT-TT.

Phase II Trial of TAS-102 in Colorectal Cancer Patients With Circulating Tumor DNA-Defined Minimal Residual Disease After Adjuvant Therapy: INTERCEPT-TT.

Study on drug sensitivity and clinical application of tumor organoid-based colorectal cancer models.

Study on drug sensitivity and clinical application of tumor organoid-based colorectal cancer models.

CF10 Displayed Improved Activity Relative to 5-FU in a Mouse CRLM Model Under Conditions of Physiological Folate.

CF10 Displayed Improved Activity Relative to 5-FU in a Mouse CRLM Model Under Conditions of Physiological Folate.

Efficacy and safety of TAS-102 plus Surufatinib in third and later line metastatic pancreatic cancer: a prospective, single center and biomarker exploratory, phase II study.

Efficacy and safety of TAS-102 plus Surufatinib in third and later line metastatic pancreatic cancer: a prospective, single center and biomarker exploratory, phase II study.

Incorporation and Repair of Epigenetic Intermediates as Potential Chemotherapy Agents.

Incorporation and Repair of Epigenetic Intermediates as Potential Chemotherapy Agents.

Targeted therapy combined with immunotherapy vs trifluridine/tipiracil with bevacizumab as late-line therapy in metastatic colorectal cancer.

Targeted therapy combined with immunotherapy vs trifluridine/tipiracil with bevacizumab as late-line therapy in metastatic colorectal cancer.

Tecovirimat is active against various MPXV strains, while cidofovir, brincidofovir, trifluridine, and gemcitabine have no detectable MPXV-specific antiviral activity.

Tecovirimat is active against various MPXV strains, while cidofovir, brincidofovir, trifluridine, and gemcitabine have no detectable MPXV-specific antiviral activity.

Effect of a Biweekly Dosing Schedule on Severe Neutropenia Induced by Trifluridine/Tipiracil in Colorectal Cancer.

Effect of a Biweekly Dosing Schedule on Severe Neutropenia Induced by Trifluridine/Tipiracil in Colorectal Cancer.

Comparison of standard and biweekly trifluridine/tipiracil plus bevacizumab regimens in advanced or recurrent colorectal cancer: a retrospective study.

Comparison of standard and biweekly trifluridine/tipiracil plus bevacizumab regimens in advanced or recurrent colorectal cancer: a retrospective study.